Gary Miller, MD
Pulmonary Disease · Washington, DCNPI 1386606952
Payments from drug & device makers
What this record shows
This record is dominated by other: $3,135 of the $5,212 with a category attached, or 60.2%. Philips North America LLC accounts for 60.2% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $1,995, 4.5 times the $446 reported in 2019.
Across 83 payments — averaging $62.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$3K
- AstraZeneca$422
- Insmed, Inc.$262
- GSK$212
- Harmony Biosciences LLC$181
- ZOLL Respicardia, Inc.$172
- plus $828 from 13 others
What the payments were for
- Food & beverage$1,75534%
- Education$3226%
- Other$3,13560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 4 | $3,135 |
| AstraZeneca | 23 | $422 |
| Insmed, Inc. | 8 | $262 |
| GSK | 10 | $212 |
| Harmony Biosciences LLC | 5 | $181 |
| ZOLL Respicardia, Inc. | 1 | $172 |
| Amgen | 7 | $154 |
| Actelion Pharmaceuticals US, Inc. | 2 | $133 |
| Sanofi | 5 | $117 |
| Verona Pharma, Inc. | 5 | $114 |
| Viatris Specialty LLC | 3 | $78 |
| Novo Nordisk | 2 | $50 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Exact Sciences | 1 | $33 |
| Astellas Pharma US Inc | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $23 |
| Pfizer | 1 | $17 |
| Medicure Pharma Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (8269) DreamStation Cpap$3,135
- remede System$172
How this compares
$5,212 in reported general payments places this provider in the 75th percentile of 56 pulmonary disease providers in District of Columbia.
See all pulmonary disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 132 | $156,098 |
| OzempicSemaglutide | 46 | $95,618 |
| Pirfenidone | 12 | $91,694 |
| EliquisApixaban | 50 | $71,063 |
| MounjaroTirzepatide | 66 | $69,698 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $53,574 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $37,638 |
| JardianceEmpagliflozin | 21 | $30,674 |
| JanuviaSitagliptin Phosphate | 24 | $22,148 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $20,525 |
| Repatha SureclickEvolocumab | 11 | $18,451 |
| Spiriva RespimatTiotropium Bromide | 12 | $17,659 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $17,098 |
| MyrbetriqMirabegron | 12 | $11,077 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $11,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $212 | $220,945235 claims |
| Novo NordiskOzempic | $50 | $95,61846 claims |
| PfizerEliquis, Paxlovid | $17 | $73,86069 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $422 | $69,31390 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $11,07712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 56 pulmonary disease providers in District of Columbia.
Other pulmonary disease in Washington
- Andrew ShorrWashington$349K
- Eric AndersonWashington$215K
- Anne OdonnellWashington$61K
- Andrew LernerWashington$19K
- Guillermo GutierrezWashington$14K
- Khalil DiabWashington$10K
- Lorenzo LeysWashington$9K
- Rebecca KrochmalWashington$9K
- Steven LernerWashington$6K
- Karen FaganWashington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.